{"nctId":"NCT00308711","briefTitle":"Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor","startDateStruct":{"date":"2006-04"},"conditions":["Cervical Ripening","Labor, Induced"],"count":1308,"armGroups":[{"label":"MVI 100","type":"EXPERIMENTAL","interventionNames":["Drug: Misoprostol vaginal insert 100 mcg"]},{"label":"MVI 50","type":"EXPERIMENTAL","interventionNames":["Drug: Misoprostol vaginal insert 50 mcg"]},{"label":"Cervidil 10 mg vaginal insert","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dinoprostone vaginal insert (Cervidil)"]}],"interventions":[{"name":"Misoprostol vaginal insert 100 mcg","otherNames":["Misopess(TM)"]},{"name":"Misoprostol vaginal insert 50 mcg","otherNames":["Misopess(TM)"]},{"name":"Dinoprostone vaginal insert (Cervidil)","otherNames":["Propess(R)","10 mg dinoprostone vaginal insert"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pregnant women at least 36 weeks gestation requiring cervical ripening and induction of labor\n\nExclusion Criteria:\n\n* No uterine scar (no previous delivery by cesarean section)\n* No multiple gestation\n* No condition that disallows use of prostaglandins for induction of labor\n* No more than 3 previous vaginal births beyond 24 weeks gestation","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Minutes From Drug Insertion to Vaginal Delivery","description":"Interval between time/date of insertion of study drug and time/date of neonate birth. This is a time-to-event analysis, there is no set time for the assessment. The endpoint occurs when the baby is born. 48 hours can be used as an approximate interval by which time most of the babies have been delivered.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1595.5","spread":null},{"groupId":"OG001","value":"2127","spread":null},{"groupId":"OG002","value":"1649.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Cesarean Section Delivery","description":"Percentage of participants with cesarean delivery after study drug was administered. There is no set assessment time or date as the woman's labor may last hours or days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Maternal/Fetal, Maternal (Post-Partum), and Neonatal Adverse Events","description":"This outcome reports the percentage of adverse events in each treatment arm spontaneously reported or observed during the study. The intrapartum period (mother is still pregnant) is called the \"Maternal/Fetal\" period; once the baby has been born, adverse events are assessed separately for the mother (Post Partum) and the baby (Neonatal). The number of adverse events was assessed separately for each of the three periods.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Pre-Delivery Oxytocin Use","description":"Incidence in each treatment group of need for oxytocin for pre-delivery induction or augmentation of labor.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"80.8","spread":null},{"groupId":"OG002","value":"69.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Cervical Ripening Success Based On Modified Bishop Score (mBS) 12 Hours After Administration of Vaginal Insert","description":"Measured the percentage of participants who achieved success on the mBS. This composite score is based on the mBS and vaginal delivery and it is measured 12 hours after insertion of the study drug. The mBS has a score of 0 when the cervix is not ripe and a score of 12 when completely ripened. The 12 hour score is compared to baseline. Using the mBS, assess at 12 hours whether each subject has met any of the following three criteria: 1) has improved (increased) the mBS by at least 3 points from baseline; 2) has reached a score of at least 6 on the mBS; or 3) has acheived a vaginal delivery.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":"3.15"},{"groupId":"OG001","value":"50","spread":"2.8"},{"groupId":"OG002","value":"60","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Minutes to Onset of Active Labor","description":"Interval from insertion of study drug to onset of active labor, defined as at least three contractions in a ten-minute period of at least moderate intensity and resulting in cervical change such as dilatation or effacement; OR at least 4 cm cervical dilatation achieved after progressive change in dilatation.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1032.5","spread":"627.2"},{"groupId":"OG001","value":"1343.7","spread":"692.0"},{"groupId":"OG002","value":"1005.2","spread":"667.1"}]}]}]},{"type":"SECONDARY","title":"Minutes to Rupture of Membranes (ROM)","description":"Interval from study drug insertion to ROM.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1285.0","spread":null},{"groupId":"OG001","value":"1364.0","spread":null},{"groupId":"OG002","value":"1123","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Stay in Minutes in Labor and Delivery Suite","description":"Minutes in Labor and Delivery (L \\& D) suite starting from insertion of the study drug to discharge from L \\& D to post partum care.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1683.6","spread":"811"},{"groupId":"OG001","value":"2010","spread":"850"},{"groupId":"OG002","value":"1729","spread":"862"}]}]}]},{"type":"SECONDARY","title":"Days in Hospital for Mother and Neonate","description":"Duration of stay in hospital for mother and neonate starting with insertion of the study drug and ending with discharge from the hospital.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"1.24"},{"groupId":"OG001","value":"4.7","spread":"1.1"},{"groupId":"OG002","value":"4.5","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.8"},{"groupId":"OG001","value":"3.5","spread":"1.2"},{"groupId":"OG002","value":"3.6","spread":"1.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":106,"n":428},"commonTop":["Foetal heart rate disorder","uterine contractions abnormal","Meconium in amniotic fluid","Perineal laceration","Chorioamnionitis"]}}}